JP2024506684A - Ｐａｒｐ７阻害物質の投与レジメン - Google Patents

Ｐａｒｐ７阻害物質の投与レジメン Download PDF

Info

Publication number
JP2024506684A
JP2024506684A JP2023548891A JP2023548891A JP2024506684A JP 2024506684 A JP2024506684 A JP 2024506684A JP 2023548891 A JP2023548891 A JP 2023548891A JP 2023548891 A JP2023548891 A JP 2023548891A JP 2024506684 A JP2024506684 A JP 2024506684A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506684A5 (enExample
Inventor
マリー バズビンダー，メリッサ
ジェイ アトリー，ルーカス
ボゾン，ビビアナ
ウェイン カンツ，ケビン
パラスラマン，スダ
マカロック，ウィリアム
ウッド，ノーラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribon Therapeutics Inc
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of JP2024506684A publication Critical patent/JP2024506684A/ja
Publication of JP2024506684A5 publication Critical patent/JP2024506684A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023548891A 2021-02-16 2022-02-15 Ｐａｒｐ７阻害物質の投与レジメン Pending JP2024506684A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163149901P 2021-02-16 2021-02-16
US63/149,901 2021-02-16
US202163275163P 2021-11-03 2021-11-03
US63/275,163 2021-11-03
PCT/US2022/016403 WO2022177877A1 (en) 2021-02-16 2022-02-15 Dosage regimens for parp7 inhibitors

Publications (2)

Publication Number Publication Date
JP2024506684A true JP2024506684A (ja) 2024-02-14
JP2024506684A5 JP2024506684A5 (enExample) 2025-02-25

Family

ID=80449181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548891A Pending JP2024506684A (ja) 2021-02-16 2022-02-15 Ｐａｒｐ７阻害物質の投与レジメン

Country Status (6)

Country Link
US (3) US20220265654A1 (enExample)
EP (1) EP4294399A1 (enExample)
JP (1) JP2024506684A (enExample)
KR (1) KR20230146593A (enExample)
TW (1) TW202245777A (enExample)
WO (1) WO2022177877A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4294399A1 (en) * 2021-02-16 2023-12-27 Ribon Therapeutics Inc. Dosage regimens for parp7 inhibitors
WO2024032410A1 (zh) * 2022-08-09 2024-02-15 成都百裕制药股份有限公司 哌嗪类化合物和pd-1抑制剂或pd-l1抑制剂的组合物以及其治疗肿瘤的用途
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019212937A1 (en) * 2018-04-30 2019-11-07 Ribon Therapeutics Inc. Pyridazinones as parp7 inhibitors
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT105058B (pt) * 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
MX2019012176A (es) * 2017-04-10 2020-02-19 Sierra Oncology Inc Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
CA3066778A1 (en) * 2017-06-21 2018-12-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP4294399A1 (en) * 2021-02-16 2023-12-27 Ribon Therapeutics Inc. Dosage regimens for parp7 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019212937A1 (en) * 2018-04-30 2019-11-07 Ribon Therapeutics Inc. Pyridazinones as parp7 inhibitors
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor

Also Published As

Publication number Publication date
US20250064803A1 (en) 2025-02-27
US20220265654A1 (en) 2022-08-25
WO2022177877A1 (en) 2022-08-25
US20240325391A1 (en) 2024-10-03
TW202245777A (zh) 2022-12-01
KR20230146593A (ko) 2023-10-19
EP4294399A1 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
US12048698B2 (en) Treatment of HER2 positive cancers
US20240325391A1 (en) Dosage regimens for parp7 inhibitors
US20220387618A1 (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
US20230310455A1 (en) Combination therapies for treatment of her2 cancer
CN114173776A (zh) 用于转移性或晚期乳腺癌患者的6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸
US20260060971A1 (en) Methods of treating solid tumors having activation fgfr3 gene alterations
JP2022180472A (ja) 癌のための併用療法
EP3574904A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
JP2021520406A (ja) Ｂｒａｆ変異を有するがんのための組合せ治療
US20250009748A1 (en) Combination therapy using substituted pyrimidin-4(3h)-ones and sotorasib
EP4301356A1 (en) Treatment of breast cancer with amcenestrant and palbociclib
JP2022500479A (ja) Ｃｄｃ７阻害剤を含む癌の治療方法
JP2025156353A (ja) 免疫調節を使用したがんの治療のための新規アプローチ
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
CN117177753A (zh) Parp7抑制剂的剂量方案
US20250268900A1 (en) Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer
KR20150003786A (ko) Pi3k 저해제 및 mek 저해제를 이용한 암 치료 방법
EP4427751A1 (en) Pharmaceutical composition comprising pi3k and dna-pk dual inhibitor for preventing or treating peripheral t cell lymphoma
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
WO2024076633A1 (en) Methods of treating estrogen receptor-mediated disorders
EP4598520A1 (en) Methods of treating estrogen receptor-mediated disorders
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260706